Publication of interim report January – March 2026
OSLO, NORWAY – May 28, 2026: Genetic Analysis AS (“GA” or the “Company”) hereby publishes the interim report for the period January – March 2026. The report is available as…
Minutes of Annual General Meeting
OSLO, NORWAY – 20 May 2026: The Annual General Meeting in Genetic Analysis AS (the “Company”) was held on Wednesday 20 May 2026 at 15:00 hours (CEST) at the Company’s…
Genetic Analysis granted a U.S. patent for companion diagnostic related to IBS treatment response
OSLO, NORWAY – 7 May 2026: Genetic Analysis AS (“GA” or “the Company”) announces today the United States Patent And Trademark Office (USPTO) has granted U.S. patent no. 12,596,121, titled…
Notice of Annual General Meeting
OSLO, NORWAY – 5 May 2026: Notice is hereby served that the annual general meeting in Genetic Analysis AS (the “Company”) will be held on Wednesday 20 May 2026 at…
Genetic Analysis AS publishes Annual Report 2025
OSLO, NORWAY – 4 May 2026: Genetic Analysis AS (the “Company”, Ticker: GEAN) hereby publishes the Annual Report for the financial year of 2025. The Annual Report is available as…
Genetic Analysis to attend DDW congress in Chicago
OSLO, NORWAY, April 30, 2026: Microbiome DX company Genetic Analysis AS (“GA”) announces its attendance at Digestive Disease Week (DDW) congress in Chicago, May 3 – May 5 2026. The company…
Genetic Analysis AS launches AInsight for AI-assisted interpretation of GA-map® Dysbiosis Test results
OSLO, NORWAY – March 12: Genetic Analysis AS (“GA” or “the Company”) today announces the launch of GA-map® Dysbiosis Test AInsight (“AInsight”), an AI-assisted interpretation platform designed to translate microbiome…
Publication of year-end report 2025
OSLO, NORWAY – February 27, 2026: Genetic Analysis AS (“GA” or the “Company”) hereby publishes the year-end report for 2025. The report is available as an attached file to this…
Genetic Analysis AS further strengthens IP portfolio with patent approval in the United States
OSLO, NORWAY – February 19, 2026: Genetic Analysis AS (“GA” or “the Company”) announces that its patent application US2017/0369941 has been allowed for grant by the United States Patent and…
Microbiome Dx Genetic Analysis announces important patent approval enhancing the use of GA-map® in Canada
OSLO, NORWAY – February 12, 2026: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces that its important patent application CA2980637) has now been allowed for grant in Canada….
Publication of interim report Q3 2025
OSLO, NORWAY – November 27, 2025: Genetic Analysis AS (“GA” or the “Company”) hereby publishes the interim report for Q3, and the first nine months of 2025. The report is…
Genetic Analysis AS announces milestone in the IBD diagnostic test development project – completion of biomarker panel for GA-map® IBD Precision Dx
OSLO, NORWAY – 17 November 2025: Microbiome DX company Genetic Analysis AS (“GA”) is pleased to announce the completion of the biomarker panel development in its ongoing IBD Precision Dx…
Genetic Analysis AS launches the GA-map® MHI GutHealth reagent kit
OSLO, NORWAY – 24 September 2025: Microbiome DX company Genetic Analysis AS (“GA”) announces the launch of a novel Research Use Only (RUO) reagent kit, the GA-map® MHI GutHealth. The…
Publication of Half-year report 2025
OSLO, NORWAY – August 27 2025: Genetic Analysis AS (“GA” or the “Company”) hereby publishes the half-year report for H1, and April – June 2025. The Half-year report is available…
Genetic Analysis AS and Pangea Laboratory LLC announces the launch of GA-map® MHI GutHealth in the USA
OSLO, NORWAY/IRVINE, CA, USA – 29 July 2025: Microbiome DX company Genetic Analysis AS (“GA”) and Pangea Laboratory LLC (“Pangea”) announces the launch of the GA-map® MHI GutHealth as a…